Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(11 sites)

Taiwan

Changhua Christian Hospital, Changhua

Chang Gung Medical Foundation, Kaohsiung City

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospita, Tainan

Mackay Memorial Hospital, Taipei

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei

Chang Gung Medical Foundation, Taoyuan District